

# The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse

Isabel M. Berwian<sup>1,2\*</sup>, Julia G. Wenzel<sup>3</sup>, Leonie Kuehn<sup>3</sup>, Inga Schnuerer<sup>1</sup>, Lars Kasper<sup>1</sup>, Ilya M. Veer<sup>3</sup>, Erich Seifritz<sup>2</sup>, Klaas E. Stephan<sup>1,4,5</sup>, Henrik Walter<sup>3,+</sup> and Quentin J. M. Huys<sup>1,2,6,7,+</sup>

**1** Translational Neuromodeling Unit, University of Zurich and ETH Zurich, Zurich, Switzerland **2** Hospital of Psychiatry, University of Zurich, Zurich, Switzerland **3** Charité Universitätsmedizin, Campus Charité Mitte, Berlin, Germany **4** Wellcome Trust Neuroimaging Centre, University College London, London, United Kingdom **5** Max Planck Institute for Metabolism Research, Cologne, Germany **6** Division of Psychiatry and Max Planck Centre for Computational Psychiatry and Ageing Research, University College London, London, United Kingdom **7** Camden and Islington NHS Foundation Trust, London, United Kingdom **+** Equal contribution **\* Corresponding author:** Isabel Berwian, Translational Neuromodeling Unit, Institute of Biomedical Engineering, University of Zurich and ETH Zurich, Wilfriedstrasse 6, 8032 Zurich, Switzerland, [berwian@biomed.ee.ethz.ch](mailto:berwian@biomed.ee.ethz.ch), +41 76 201 29 43

**Running title:** Antidepressant effects on RSFC in remitted MDD

**Keywords:** antidepressant discontinuation; depression; resting-state functional connectivity; relapse; seed-based analyses; posterior default mode network

## Abstract

**Background:** The risk of relapsing into depression after stopping antidepressants is high, but no established predictors exist. Resting-state functional magnetic resonance imaging (rsfMRI) measures may help predict relapse and identify the mechanisms by which relapses occur.

**Method:** rsfMRI data were acquired from healthy controls and from patients with remitted major depressive disorder on antidepressants who were intent on discontinuing their medication. Patients went on to discontinue their antidepressants, were assessed a second time either before or after discontinuation and followed up for six months to assess relapse. A seed-based functional connectivity analysis was conducted focusing on the left subgenual anterior cingulate cortex and left posterior cingulate cortex. Seeds in the amygdala and dorsolateral prefrontal cortex were explored.

**Results:** 44 healthy controls (age: 33.8 (10.5), 73% female) and 84 patients (age: 34.23 (10.8), 80% female) were included in the analysis. 29 patients went on to relapse and 38 remained well. Seed-based analysis failed to reveal differences in functional connectivity between patients and controls; and between relapsers and non-relapsers. Although overall there was no effect of antidepressant discontinuation, amongst non-relapsers discontinuation resulted in an increased functional connectivity between the right dorsolateral prefrontal cortex and the parietal cortex.

**Conclusion:** No abnormalities in resting-state functional connectivity were detected in remitted patients on antidepressant medication. Resilience to relapse after open-label antidepressant discontinuation was associated with changes in the connectivity between the dorsolateral prefrontal cortex and the posterior default mode network.

# 1 Introduction

A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)(1). However, this does not imply that the illness is cured as one in three of those achieving remission experience a relapse within six months after ADM discontinuation(2). Indeed, the burden of depressive illnesses is in no small part due to their chronic nature with frequent relapses over the lifetime(3; 4). Hence, the management of relapses is of paramount importance. In this situation, predictors of relapse risk are urgently needed to guide decision-making at key decision points such as the discontinuation of ADM after remission has been achieved.

Unfortunately, standard demographic and clinical variables appear to have very limited predictive power(5), requiring attention to be turned to more complex measurements. Here, we examined resting-state functional connectivity - a complex yet clinically feasible neuroimaging procedure(6).

Indeed, a growing body of research has examined resting-state functional connectivity (RSFC) in the context of depression, treatment response and relapse. The subgenual anterior cingulate cortex (sgACC) appears to have a particularly central role in the illness and treatment of depression(7; 8): neuroimaging measures of metabolic activity within this region have been shown to have predictive power for response to antidepressant and other treatments(9; 10) and RSFC of this region is predictive of relapse independent of ADM discontinuation(11; 12). Furthermore, abnormalities in RSFC in both the depressed (e.g. (13)) and remitted state (e.g. (14)) have been documented in this brain region.

The sgACC appears to exert its influence in part through connectivity to voxels in the so-called "default mode network" (DMN), the central executive network (CEN), the salience network (SN), the amygdala and the hippocampus. In MDD, the connectivity within the anterior and posterior DMN is increased and connectivity between the anterior DMN and the affective and salience network and the sgACC is also altered(15; 16). In contrast, connectivity within the CEN and SN and connectivity to the posterior DMN are reduced(15; 16). Connectivity changes in these regions have also been observed in remitted patients off medication and in populations with correlates of depression such as trauma, childhood maltreatment, subclinical depression and familial risk in children. These include increased connectivity between the sgACC and both the medial prefrontal cortex (mPFC) and the posterior cingulate cortex (PCC), as well as bidirectional changes in connectivity between the sgACC and the dorsolateral PFC (dlPFC), the amygdala and the hippocampus((17; 18; 19; 20; 21; 22; 23; 24; 25; 14); though see also (26)). Of note, decreased interhemispheric sgACC connectivity from the left to the right has been suggested as a marker of resilience to relapse in patients off medication(12), while increased connectivity between the sgACC and regions in the CEN differentiates patients who will experience a relapse and those who will not(11). A reduction in connectivity within the DMN has also been reported amongst medicated patients and those with recurrent illness(27).

The results of studies examining the impact of ADM initiation on connectivity are heterogeneous(28; 29; 30; 31; 32; 33; 34; 35; 36; 37; 38; 39). One of the more replicated findings is a decrease in connectivity between PCC and various brain regions (including amygdala(31), right inferior temporal gyrus(36), right inferior frontal gyrus(33)), suggesting a normalisation of increased PCC connectivity with these regions in comparison to the prior, medication-free, state. Increases between the PCC and the ACC and mPFC have been reported in patients who receive treatment, but do not remit(32).

Outstanding gaps in this literature are 1) whether RSFC connectivity differences seen in the remitted unmedicated state are also present in the remitted medicated state; 2) whether pre-discontinuation RSFC differs between

patients who relapse after discontinuation and those who remain well; 3) the effects of discontinuation on RSFC; and 4) to what extent changes in RSFC due to discontinuation are related to future relapses. We here examine this in the context of the AIDA study - a two-centre observational randomized study that followed patients as they discontinued their ADM for six months. Based on the reviewed literature, we focused on the sgACC as seed region to address questions 1 and 2 and on the PCC for questions 3 and 4.

## 2 Methods and Materials

### 2.1 Study Design




Figure 1: Study Design: Remitted patients on antidepressant medication (ADM) and matched healthy controls (HC) were included in the study and assessed during main assessment 1 (MA1). Patients were randomised to arms 1W2 or 12W. In arm 12W, they started discontinuation only after MA2. In arm 1W2, they discontinued their medication prior to the second main assessment MA2. After discontinuation, all patients were followed up for six months to ascertain relapses. Comparison of patient and control groups at MA1 was used to examine the remitted medicated state cross-sectionally; comparison at MA1 of patients who did and did not relapse to examine potential predictors of relapse; the interaction between MA1/2 and groups 1W2/12W to examine the impact of discontinuation; and the interaction between MA1/2 and patients who went on to relapse and those who remained well in group 1W2 to examine changes due to discontinuation that led to relapse or resilience.

The AIDA study design is depicted in Figure 1. Briefly, we focused on remitted patients on ADM who wanted to discontinue their medication. Participants were randomised to one of the two study arms. In arm 1W2, participants underwent the first main assessment (MA1), then gradually discontinued their medication over up to 18 weeks, and then underwent a second main assessment (MA2). In arm 12W, participants underwent two main assessments before discontinuation.

After discontinuation, all patients were contacted by telephone at weeks 1, 2, 4, 6, 8, 12, 16 and 21 to assess relapse status. Structured clinical interviews were performed if a relapse was suspected (SCID-I(40)). If these criteria were fulfilled, they underwent an in-person final assessment (FA), otherwise the final assessment took place in week 26. Healthy controls (HC) matched for age, sex and education were only assessed once (MA1).

All patients underwent a resting-state functional magnetic resonance imaging (rsfMRI), self- and observer-rated reports during each main assessment (MA1 and MA2) and HC once at MA1. See supplementary section S1.2 for observer-rated and self-report measures. Participants were recruited between July 2015 and January 2018.

## 2.2 Participants

The AIDA study recruited participants who had experienced one severe(41) or multiple depressive episodes; had initiated antidepressant treatment during the last depressive episode and now achieved stable remission; and had reached the decision to discontinue their medication independent from and prior to study participation. Detailed inclusion and exclusion criteria are listed in the supplementary section S1.1. All participants gave informed written consent and received monetary compensation for the time of participation. Ethical approval for the study was obtained from the cantonal ethics commission Zurich (BASEC: PB\_2016-0.01032; KEK-ZH: 2014-0355) and the ethics commission at the Campus Charité-Mitte (EA 1/142/14).

## 2.3 Seed Region Selection




Figure 2: Seeds and Mask: Depicted are the seeds (A) used in the analysis and the affective mask (B) containing all voxels of interest. sgACC = subgenual anterior cingulate cortex; PCC = posterior cingulate cortex, dlPFC = dorsolateral prefrontal cortex

Seven seeds of interest (Figure 2A) were identified based on existing literature. The sgACC seeds with MNI coordinates  $\pm 4, 21, -8$  were chosen as they had been used in several previous studies with patients with remitted MDD(17; 21; 22; 23; 11) and clearly mapped on the anatomical region of the sgACC during visual inspection. For the left PCC we chose the MNI coordinates  $-3, -39, 39$  as identified by Fox and colleagues(42) as a central part of the task-negative network and were reported to have normalised RSFC after ADM initiation(35). dlPFC coordinates (MNI  $\pm 37, 26, 31$ ) were taken from Sheline and colleagues(43) and have been used widely in the literature. Unless stated otherwise, seeds were created by putting a 6mm sphere around the coordinates. Amygdala seeds were extracted from the Harvard-Oxford Subcortical Probability Atlas by including all voxels with at least 80% probability of being in the amygdala. For each analysis, one seed was designated a priori as the main seed of interest and the other six as exploratory seeds.

## 2.4 Resting-state fMRI analysis

### 2.4.1 Image acquisition and preprocessing

The sequences used for image acquisition are described in the supplementary section S1.4. Imaging data was preprocessed with a FSL (FMRIB Software Library v5.0) pipeline detailed in supplementary section S1.5.

### 2.4.2 Connectivity estimation

First level analyses were conducted with the CONN toolbox(44). We included motion regressors (see section motion correction for details), 10 regressors computed using aCompCor in the CONN toolbox (5 principal components of white matter and cerebrospinal fluid signals each), and bandpass filtered the data to retain frequencies between 0.01 and 0.1 Hz. All covariates were also regressed out of the seed regions. Then, the average signal of all voxels within subject-specific grey matter masks of each seed was computed and correlated with all voxels in the brain. Resulting correlation coefficients were z-transformed for second-level analyses.

### 2.4.3 Motion and study site effects

Analyses to control for effects of motion and study site are described in detail in supplementary section S1.6 and S1.7. Subjects with a framewise displacement (FD) of 1mm from one volume to the next and with a mean SNR smaller than 30 were excluded from further analyses.

### 2.4.4 Second-level analyses

Second-level analyses were conducted with SPM12 (version: v7219). For all analyses with our chosen main seed, we report peak-level results family-wise error (FWE) corrected at the voxel level at 0.05 and depict the respective clusters in figures. Altered RSFC of the selected seeds in acute and remitted depression has mainly been reported for voxels which are part of the DMN, the CEN, the SN, the amygdala and the hippocampus(16; 15; 17; 19; 21; 22; 23; 14). As FWE-corrected results depend on the search volume of the analysis, we constructed an "affective mask" containing all voxels within the DMN, the CEN and the SN, as well as voxels within anatomical masks of the bilateral amygdalae and the hippocampi (Figure 2B) as these areas show abnormal RSFC in affective disorders. Exploratory analyses were considered significant after Bonferroni correction for all six seeds at  $p=0.0083$ .

Our first analyses focused on the first assessment MA1. To identify abnormalities persisting into the remitted medicated state we compared RSFC between the left sgACC and the affective mask between patients and HC using an independent-sample t-test. To identify markers of prospective relapse, we repeated this analysis comparing patients who did and did not go on to relapse. Exploratory analyses examined the RSFC between the affective mask and the right sgACC, the left PCC, right and left amygdala and right and left dIPFC seed regions.

Next, we examined the impact of discontinuation. To test the hypothesis that RSFC between the PCC and the affective mask would increase due to discontinuation, we applied a mixed-design analysis of variance (ANOVA) with group (1W2 and 12W) as between-subject factor and time point as within-subject factor (MA1 and MA2). Where significant interaction effects were found, we conducted the following post-hoc tests: paired sample t-test in group 1W2 to identify changes related to discontinuation; paired sample t-test in group 12W to investigate test-retest reliability and an independent sample t-test between group 1W2 and 12W at MA1 to verify that no random allocation differences occurred prior to discontinuation. We repeated this analyses using the right and left sgACC, right and left amygdala and right and left dIPFC as seeds for exploratory analyses.

Finally, we attempted to gain insight into how the effects of discontinuation might relate to relapse. For this, the above analyses were repeated within group 1W2 only using relapse as between-subjects factor. Post-hoc paired sample t-tests were performed within the relapse group to identify changes related to relapse and paired t-tests in the no-relapse group to identify changes related to resilience.

Additional sanity checks and exploratory analyses are described in supplementary section S1.8.

#### **2.4.5 Covariates**

RSFC that were found to differ significantly between or within groups were correlated with several covariates including age, gender and site as covariates of no interest and rumination score, residual depression score, medication load and disease severity. Computation of medication load and severity factor is outlined in supplementary section S1.3.

Table 1: Participant characteristics

Variable <sup>a</sup>	Patients vs. Healthy controls			Relapsers vs. Non-relapsers		
	Patients (n = 84)	Healthy controls (n = 44)	P value	Relapsers (n = 29)	Non-relapsers (n = 38)	P Value
<b>Demographics</b>						
Age	34.23 (10.8)	33.8 (10.5)	0.83	36.76 (11.1)	31.79 (10.3)	0.062
Male sex, No. (%)	17 (20)	12 (27)	0.37	7 (24)	6 (16)	0.39
Site Zürich, No. (%)	61 (73)	27 (61)	0.19	20 (69)	28 (74)	0.67
<b>Clinical measures</b>						
Number of prior episodes	-	-	-	2.76 (1.8)	2.32 (1.6)	0.29
Residual depression <sup>b</sup>	3.38 (3.7)	0.70 (1.1)	<0.001	3.52 (5.14)	2.87 (2.3)	0.49
Disease severity <sup>c</sup>	-	-	-	0.08 (0.4)	-0.05 (0.33)	0.14
Medication load <sup>c</sup>	-	-	-	0.007 (0.004)	0.008 (0.004)	0.33
Month of ADM intake <sup>d</sup>	-	-	-	24	28	0.77
Psychotherapy <sup>c</sup>	-	-	-	0.40 (0.39)	0.39 (0.39)	1
Comorbidities <sup>b</sup>	-	-	-	0.72 (1.03)	0.61 (1.03)	0.64
Days of tapering	-	-	-	52.86 (40.18)	51.53 (43.74)	0.90
<b>Covariates of interest</b>						
Brooding <sup>b</sup>	9.65 (2.6)	8.14 (2.3)	0.001	10.55 (2.77)	8.71 (1.9)	0.002
<b>Imaging measures</b>						
Framewise displacement	0.11 (0.05)	0.10 (0.05)	0.42	0.12 (0.07)	0.11 (0.04)	0.37

a) Unless stated otherwise, mean (SD) are shown; b) Determined as follows: residual depression: Inventory of Depressive Symptomatology-Clinician Rated(45); brooding: brooding subscale of the German version of the Response Style Questionnaire(46); comorbidities: number of past and present psychiatric diagnoses; c) Computation of the variables is described in the supplementary section S1.3; d) Median is provided and a non-parametric Wilcoxon rank sum test was applied to test significance.



## 3 Results

### 3.1 Participants




Figure 3: Consort Diagram: Depicted are reasons for dropouts and exclusion for patients throughout the study. (+ X) indicates the number of participants who either relapsed or did not relapse but did not have useable data at MA2.

The consort diagram (Figure 3) shows numbers at each study stage and reasons for dropouts. Briefly, 66 healthy controls were included. Of these, 7 dropped out before MA1, 4 were considered pilot data, 4 did not have useable resting-state data, 1 was excluded from all analyses due to a lack of adherence to instructions and 6 were excluded due to motion. Demographic and clinical characteristics are displayed in Table 1. Patients scored higher on the rumination brooding subscale. This was particularly accentuated in patients who went on to relapse. 69% of our sample took a selective serotonin reuptake inhibitor, 27% a serotonin-norepinephrine reuptake inhibitor and 4% an antidepressant from a different class.

Table 2: Significant discontinuation relapse effects for the dorsolateral prefrontal cortex

Contrast	Region (BA)	Peak MNI coordinates			k	p (cluster)	T-Value	Z	p (peak)
		x	y	z					
Interaction in F-test	Parietal cortex (BA 7)	14	-66	38	30	0.002	5.05	5.21	0.001
	PCC (BA 23)	12	-54	14	18	0.006	5.06	5.2	0.001
Paired T-test in non-relapsers	Parietal cortex (BA 7)	14	-66	36	30	< 0.001	8.2	5.43	0.001

BA = Brodmann area, MNI = Montreal Neurological Institute, PCC = posterior cingulate cortex

### 3.2 Motion and site effects

Comparing participants with high and low motion during MA1 yielded no significant difference between these groups for any of the seeds. Hence, we decided to only exclude participants with FD > 1 between two volumes but added no additional motion regressors and did not censor any scans with stick regressors. There was an effect of site on the temporal signal-to-noise ratio ( $t(126)=7.76$ ,  $p<0.001$ , Figure S1). To examine if this impacted significant effects, we correlate the according RSFC with site as covariate of no interest.

### 3.3 Overall connectivity

Overall seed connectivity across all participants at MA1 replicated patterns established in the literature (Figure S2).

### 3.4 The remitted and medicated state

The left sgACC was designated as the main a-priori seed. RSFC with voxels in the affective mask did not differ between remitted patients on ADM and controls. No differences were found for any of the exploratory seeds.

### 3.5 Relapse effects

The left sgACC was designated as the main a-priori seed. RSFC with voxels in the affective mask did not differ between patients who did and did not go on to relapse. No differences were found for any of the exploratory seeds.

### 3.6 Discontinuation effects

The left PCC was designated as the main a-priori seed. RSFC with voxels in the affective mask did not show an interaction between time (MA1/2) and group (1W2/12W). No interaction effects were found for any of the exploratory seeds.

### 3.7 Relationship between discontinuation and relapse

A significant interaction between discontinuation and relapse emerged for RSFC between the right dlPFC and two peaks in the right posterior DMN, namely in the parietal cortex (Figure 4A,B; Table 2) and the posterior cingulate




Figure 4: Discontinuation relapse interaction effect: A) Depicted are clusters for significant interactions between discontinuation and relapse between a seed in the right dorsolateral prefrontal cortex (dIPFC, magenta) and the parietal cortex (red) and the posterior cingulate cortex (PCC, green) and a paired t-test in non-relapsers only for RSFC between right dIPFC and the parietal cortex (blue). B-D) The Fisher z-transformed average functional connectivity between the right dIPFC and the surviving clusters in the parietal cortex and the PCC is depicted for the interaction between relapsers and non-relapsers (B and D, respectively) and the paired t-test in non-relapsers (C) for the interaction effect in relation to the parietal cortex shown in (B). Error bars indicate standard errors.

cortex (Figure 4A,D). Post-hoc tests did not reveal differences between relapsers and non-relapsers before discontinuation. The significant interaction was driven by an increase in RSFC in patients who discontinued but did not go on to relapse: RSFC between the right dlPFC and the right parietal cortex increased with discontinuation in those who remained well (Figure 4A,C; note the slight shift in the parietal cortex for the post-hoc test depicted in blue), while it decreased numerically without reaching statistical significance in those who went on to relapse. None of the post-hoc tests on the connectivity between right dlPFC and PCC reached significance. These effects did not remain significant when including participants with more than 1mm FD and censoring the scans with stick regressors.

### 3.8 Exploratory analyses without correction for multiple comparisons

No significant effects emerged for any of the exploratory seeds in any of the analyses when we dropped the correction for multiple comparison for number of seeds and set the required significance level to 0.05 FWE-corrected. In Table S1, we additionally report results for RSFC for our main seeds for all analyses at an uncorrected significance level of 0.001.

### 3.9 Covariates

We correlated RSFC between the right dlPFC and the cluster in the parietal cortex in non-relapsers before they discontinued as well as the change accompanying the discontinuation with our pre-specified covariates, but found no significant correlations.

## 4 Discussion

We examined resting-state functional connectivity in the context of antidepressant discontinuation in stable remission from Major Depressive Disorder. There are several negative results that are in part notable because the analyses focused on the sgACC and other well-established regions as seeds, and a narrowed set of regions as targets. First, we found no difference between remitted, medicated patients and matched controls. Second, patients who went on to relapse after ADM discontinuation did not differ from those who remained well. Third, discontinuation did not result in changes in RSFC between the PCC and voxels within our affective mask, nor any of the exploratory seeds.

The only positive finding pertains to the subgroup of patients who were tested before and after discontinuation. Only those who remained well during the follow-up period showed an increase in RSFC between the dlPFC and two areas in the posterior DMN, namely the parietal cortex and the PCC, whereas patients who went on to relapse did not show this increase and instead showed a numerical decrease that did not reach statistical significance.

Before discussing potential interpretations of the individual null findings, we highlight the difficulties inherent in interpreting the absence of an effect, and we note the problems around reliability of RSFC measures for brief scans as in our study(47). Although these results do not provide evidence for the absence of effects, power considerations can guide the interpretation by suggesting the size of effects a study of this size should have identified. Two-tailed two-sample t-tests comparing 84 patients to 44 healthy controls and 29 relapsers to 38 non-relapsers have a power of 0.8 to detect medium ( $d=0.52$ ) and large ( $d=0.70$ ) group differences, respectively, and a power of 0.95 to detect effects of  $d=0.67$  and  $0.90$ , respectively (using G\*Power 3.1(48)). As such, large effects

above 0.5 are unlikely, and hence we judge it unlikely that resting-state connectivity revealed with a seed-based approach based on short scans as in this study have clinical utility(49).

The absence of significant RSFC differences between remitted MDD patients on ADM and healthy never-depressed controls contrasts with results in the literature(21; 14). The sample size in the current study was larger than in most previous studies. We also carefully excluded possible differences in the analysis pipelines. The only major difference between previous and the present study is the medication status: all previous involving remitted patients focused on unmedicated samples(17; 19; 21; 22; 23; 14). In contrast, our patient group had been medicated for a median duration of two years. The interpretation of an absence of previously reported effects is of course difficult. Nevertheless, the absence of findings in our sample compared with the existence of effects in unmedicated samples raises the possibility that longer-term treatment might broadly normalise abnormal RSFC of the sgACC as well as of other seeds to the DMN, the CEN and SN in patients with sustained remission in response to such treatment. The absence of increased RSFC in the DMN is particularly striking given that our patient sample in the remitted and medicated state was still characterised by slightly increased rumination as assessed through self-report(50). However, our study design does not allow us to disentangle a potential normalisation from the effects antidepressants have on the BOLD signal(51; 52).

The absence of differences in RSFC between patients who went on to relapse and patients who remained well after ADM discontinuation is similarly surprising, given that relapse and resilience independent of discontinuation have been reported to be associated with abnormal RSFC of the sgACC(11; 12). We again note that our sample was assessed in the medicated state before discontinuation. The absence of a difference in our study raises the possibility that previous findings relate more broadly to relapse risk, and that our lack of findings speaks only to the specific induction of relapse through discontinuation. Such a discrepancy might mirror results from clinical predictors such as number of prior episodes, which are thought to increase the risk of overall relapse(53). Two meta-analyses examining the role of number of prior episodes in relapse after ADM discontinuation, however, came to diametrically opposing conclusions(54; 55). These results suggests that the number of prior episodes might relate to overall relapse risk, but not to relapse risk specifically after ADM discontinuation. It is interesting to consider why connectivity appears to have higher prognostic value in current MDD compared to remitted MDD(12), and why reactivating depression-relevant cognitions also led to stronger predictive performance(56). One possible explanation could be provided by Teasdale's differential activation hypothesis(57; 58) according to which depressogenic thoughts and hence depression-related neural activity patterns need to be reactivated in the remitted state in order to be visible(59).

Next, ADM discontinuation did not reveal any effects. This result, again, is unexpected given that ADM initiation has been shown to induce changes in the connectivity of the PCC(36; 31; 33). One potential explanation could be that the timing of the second measurement five half-lives after ADM discontinuation was too early to see effects. This would in turn suggest a normalisation of RSFC lasting into the unmedicated state.

Finally, our data suggests that an increase in RSFC between the right dIPFC and the posterior DMN, in particular the parietal cortex, relates to resilience to relapse after ADM discontinuation. An effect of this kind was expected a priori as it reflects prior findings showing a decrease in PCC connectivity with ADM initiation(36; 31; 33). However, unlike previous reports of an increase in the RSFC of the CEN in those who go on to relapse(11), we here observed an increase in right dIPFC-parietal connectivity in patients who remained well. These findings hence point towards a compensatory effect in response to discontinuation that might protect patients from relapse. While the default mode has been related to rumination, the right dIPFC has been extensively related to

regulation(60) and conceptual-emotional information integration(61). It is hence tempting to speculate that the increase in connectivity might reflect emotion regulation strategies and rumination, both of which influence the course of depression(62; 63).

#### **4.1 Limitations and Strengths**

The study has both strength and limitations. Amongst its strengths is that, to our knowledge, this is the first study examining neurobiological effects in the context of ADM discontinuation and relapse thereafter. The lack of findings and replications in our study, however, might result from some of its limitations. First, the resting-state scan was only 5.5min, which is relatively short. Second, the evidence in favour of abnormal RSFC of the sgACC, on which we based our hypotheses and analyses, is admittedly heterogeneous and also does rely on partially overlapping samples(17; 21; 22; 23). Third, the signal-to-noise ratio differed between the study sites, potentially reducing the power to find effects in the bigger sample from Zurich. Fourth, the fact that patients were on medication from several classes might have increased the heterogeneity of the medications' influence on RSFC and in that it reduced the power to identify significant effects. Fifth, no standard approach for motion correction exists. Hence, cut-off choices are arbitrary. To avoid spurious correlation due to motion(64; 65), we choose a priori a more conservative criterion by excluding all participants with more than 1mm FD. Sixth, the naturalistic design does not allow us to disentangle pharmacological effects of discontinuation from the potential psychological effect of knowing that the ADM is discontinued. Finally, these analyses followed previous studies of RSFC in depression, which primarily used a seed-based approach. More advanced analyses could yet reveal meaningful changes.

#### **4.2 Conclusion**

We found no RSFC differences between remitted, medicated patients and healthy controls, between relapsers and non-relapsers or as a consequence of discontinuation. This raises the possibility - but emphatically does not show - that antidepressants normalise RSFC and that this normalisation persists at least for a brief period into the unmedicated state. We did, however, find tentative evidence for a potential marker of resilience to relapse after ADM discontinuation in terms of an increased connectivity between the right dIPFC and the posterior DMN.

## **Acknowledgements**

This study was principally funded by a Swiss National Science Foundation grant (320030L\_153449 / 1) to QJMH and by a Deutsche Forschungsgemeinschaft grant (WA 1539/5-1) to HW. Additional funds were provided by a the Clinical Research Priority Program "Molecular Imaging" at the University of Zurich to KES. KES was additionally supported by the René and Susanne Braginsky Foundation.

## **Conflicts of interest**

All authors declare no conflicts of interest. The funders had no role in the design, conduct or analysis of the study and had no influence over the decision to publish.

## **Contributions**

QJMH and HW conceived and designed the study with critical input by KES and ES. IMB, JW and LKu collected the data under the supervision of QJMH and HW. KES was the study sponsor in Zurich. QJMH, ES, KES and HW acquired funding for the study. IMB planned and performed the analyses and wrote the manuscript under supervision of QJMH. LKa and IMV gave advice on the analyses. All authors provided critical comments, read and approved the manuscript.

## References

- [1] Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, *et al.* (2006): Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. *N Engl J Med* 354:1231–42.
- [2] Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, *et al.* (2003): Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. *Lancet* 361:653–61.
- [3] Angst J, Gamma A, Sellaro R, Lavori PW, Zhang H (2003): Recurrence of bipolar disorders and major depression. a life-long perspective. *Eur Arch Psychiatry Clin Neurosci* 253:236–240.
- [4] Lépine JP, Briley M (2011): The increasing burden of depression. *Neuropsychiatr Dis Treat* 7:3–7.
- [5] Berwian IM, Walter H, Seifritz E, Huys QJ (2017): Predicting relapse after antidepressant discontinuation - a systematic review. *Psychological Medicine* 47:426–437.
- [6] O'Connor EE, Zeffiro TA (2019): Why is clinical fmri in a resting state? *Front Neurol* 10:420.
- [7] Dichter GS, Gibbs D, Smoski MJ (2015): A systematic review of relations between resting-state functional-mri and treatment response in major depressive disorder. *J Affect Disord* 172:8–17.
- [8] Dunlop BW, Mayberg HS (2014): Neuroimaging-based biomarkers for treatment selection in major depressive disorder. *Dialogues Clin Neurosci* 16:479–90.
- [9] Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, *et al.* (1997): Cingulate function in depression: a potential predictor of treatment response. *Neuroreport* 8:1057–61.
- [10] McGrath CL, Kelley ME, Dunlop BW, Holtzheimer PE 3rd, Craighead WE, Mayberg HS (2014): Pretreatment brain states identify likely nonresponse to standard treatments for depression. *Biol Psychiatry* 76:527–35.
- [11] Langenecker SA, Jenkins LM, Stange JP, Chang YS, DelDonno SR, Bessette KL, *et al.* (2018): Cognitive control neuroimaging measures differentiate between those with and without future recurrence of depression. *Neuroimage Clin* 20:1001–1009.
- [12] Workman CI, Lythe KE, McKie S, Moll J, Gethin JA, Deakin JFW, *et al.* (2017): A novel resting-state functional magnetic resonance imaging signature of resilience to recurrent depression. *Psychol Med* 47:597–607.
- [13] Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, *et al.* (2007): Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. *Biol Psychiatry* 62:429–37.
- [14] Workman CI, Lythe KE, McKie S, Moll J, Gethin JA, Deakin JF, *et al.* (2016): Subgenual cingulate-amygdala functional disconnection and vulnerability to melancholic depression. *Neuropsychopharmacology* 41:2082–90.
- [15] Mulders PC, van Eijndhoven PF, Schene AH, Beckmann CF, Tendolkar I (2015): Resting-state functional connectivity in major depressive disorder: A review. *Neurosci Biobehav Rev* 56:330–44.
- [16] Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA (2015): Large-scale network dysfunction in major depressive disorder: A meta-analysis of resting-state functional connectivity. *JAMA Psychiatry* 72:603–11.



- [17] Bhaumik R, Jenkins LM, Gowins JR, Jacobs RH, Barba A, Bhaumik DK, *et al.* (2017): Multivariate pattern analysis strategies in detection of remitted major depressive disorder using resting state functional connectivity. *Neuroimage Clin* 16:390–398.
- [18] Chai XJ, Hirshfeld-Becker D, Biederman J, Uchida M, Doehrmann O, Leonard JA, *et al.* (2016): Altered intrinsic functional brain architecture in children at familial risk of major depression. *Biol Psychiatry* 80:849–858.
- [19] Gaffrey MS, Luby JL, Botteron K, Repovš G, Barch DM (2012): Default mode network connectivity in children with a history of preschool onset depression. *J Child Psychol Psychiatry* 53:964–72.
- [20] Heringa RJ, Birn RM, Ruttle PL, Burghy CA, Stodola DE, Davidson RJ, *et al.* (2013): Childhood maltreatment is associated with altered fear circuitry and increased internalizing symptoms by late adolescence. *Proc Natl Acad Sci U S A* 110:19119–24.
- [21] Jacobs RH, Jenkins LM, Gabriel LB, Barba A, Ryan KA, Weisenbach SL, *et al.* (2014): Increased coupling of intrinsic networks in remitted depressed youth predicts rumination and cognitive control. *PLoS One* 9:e104366.
- [22] Jacobs RH, Barba A, Gowins JR, Klumpp H, Jenkins LM, Mickey BJ, *et al.* (2016): Decoupling of the amygdala to other salience network regions in adolescent-onset recurrent major depressive disorder. *Psychol Med* 46:1055–67.
- [23] Jenkins LM, Stange JP, Barba A, DeIDonno SR, Kling LR, Briceño EM, *et al.* (2017): Integrated cross-network connectivity of amygdala, insula, and subgenual cingulate associated with facial emotion perception in healthy controls and remitted major depressive disorder. *Cogn Affect Behav Neurosci* 17:1242–1254.
- [24] Philippi CL, Motzkin JC, Pujara MS, Koenigs M (2015): Subclinical depression severity is associated with distinct patterns of functional connectivity for subregions of anterior cingulate cortex. *J Psychiatr Res* 71:103–11.
- [25] Thomason ME, Marusak HA, Tocco MA, Vila AM, McGarragle O, Rosenberg DR (2015): Altered amygdala connectivity in urban youth exposed to trauma. *Soc Cogn Affect Neurosci* 10:1460–8.
- [26] Bessette KL, Jenkins LM, Skerrett KA, Gowins JR, DeIDonno SR, Zubieta JK, *et al.* (2018): Reliability, convergent validity and time invariance of default mode network deviations in early adult major depressive disorder. *Front Psychiatry* 9:244.
- [27] Yan CG, Chen X, Li L, Castellanos FX, Bai TJ, Bo QJ, *et al.* (2019): Reduced default mode network functional connectivity in patients with recurrent major depressive disorder. *Proc Natl Acad Sci U S A* 116:9078–9083.
- [28] An J, Wang L, Li K, Zeng Y, Su Y, Jin Z, *et al.* (2017): Differential effects of antidepressant treatment on long-range and short-range functional connectivity strength in patients with major depressive disorder. *Sci Rep* 7:10214.
- [29] Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, *et al.* (2005): Antidepressant effect on connectivity of the mood-regulating circuit: an fmri study. *Neuropsychopharmacology* 30:1334–44.
- [30] Andreescu C, Tudorascu DL, Butters MA, Tamburo E, Patel M, Price J, *et al.* (2013): Resting state functional connectivity and treatment response in late-life depression. *Psychiatry Res* 214:313–21.

- [31] Cullen KR, Klimes-Dougan B, Vu DP, Westlund Schreiner M, Mueller BA, Eberly LE, *et al.* (2016): Neural correlates of antidepressant treatment response in adolescents with major depressive disorder. *J Child Adolesc Psychopharmacol* 26:705–712.
- [32] Goldstein-Piekarski AN, Staveland BR, Ball TM, Yesavage J, Korgaonkar MS, Williams LM (2018): Intrinsic functional connectivity predicts remission on antidepressants: a randomized controlled trial to identify clinically applicable imaging biomarkers. *Transl Psychiatry* 8:57.
- [33] Karim HT, Andreescu C, Tudorascu D, Smagula SF, Butters MA, Karp JF, *et al.* (2017): Intrinsic functional connectivity in late-life depression: trajectories over the course of pharmacotherapy in remitters and non-remitters. *Mol Psychiatry* 22:450–457.
- [34] Li B, Liu L, Friston KJ, Shen H, Wang L, Zeng LL, *et al.* (2013): A treatment-resistant default mode subnetwork in major depression. *Biol Psychiatry* 74:48–54.
- [35] Posner J, Hellerstein DJ, Gat I, Mechling A, Klahr K, Wang Z, *et al.* (2013): Antidepressants normalize the default mode network in patients with dysthymia. *JAMA Psychiatry* 70:373–82.
- [36] Qin J, Shen H, Zeng LL, Jiang W, Liu L, Hu D (2015): Predicting clinical responses in major depression using intrinsic functional connectivity. *Neuroreport* 26:675–80.
- [37] Sikora M, Heffernan J, Avery ET, Mickey BJ, Zubieta JK, Peciña M (2016): Salience network functional connectivity predicts placebo effects in major depression. *Biol Psychiatry Cogn Neurosci Neuroimaging* 1:68–76.
- [38] Wang L, Xia M, Li K, Zeng Y, Su Y, Dai W, *et al.* (2015): The effects of antidepressant treatment on resting-state functional brain networks in patients with major depressive disorder. *Hum Brain Mapp* 36:768–78.
- [39] Weinstein JJ, Rogers BP, Taylor WD, Boyd BD, Cowan RL, Shelton KM, *et al.* (2015): Effects of acute tryptophan depletion on raphé functional connectivity in depression. *Psychiatry Res* 234:164–71.
- [40] Wittchen HU, Fydrich T (1997): *Strukturiertes klinisches Interview für DSM-IV. Manual zum SKID-I und SKID-II*. Göttingen, DE: Hogrefe.
- [41] Wakefield JC, Schmitz MF (2013): When does depression become a disorder? Using recurrence rates to evaluate the validity of proposed changes in major depression diagnostic thresholds. *World Psychiatry* 12:44–52.
- [42] Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME (2005): The human brain is intrinsically organized into dynamic, anticorrelated functional networks. *Proc Natl Acad Sci U S A* 102:9673–8.
- [43] Sheline YI, Price JL, Yan Z, Mintun MA (2010): Resting-state functional mri in depression unmasks increased connectivity between networks via the dorsal nexus. *Proc Natl Acad Sci U S A* 107:11020–5.
- [44] Whitfield-Gabrieli S, Nieto-Castanon A (2012): Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. *Brain Connect* 2:125–41.
- [45] Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996): The inventory of depressive symptomatology (IDS): psychometric properties. *Psychol Med* 26:477–86.

- [46] Huffziger S, Kühner C (2012): Die Ruminationsfacetten Brooding und Reflection: Eine psychometrische Evaluation der deutschsprachigen Version RSQ-10D. *Z Klin Psychol und Psychother* 41:38–46.
- [47] Zuo XN, Xu T, Milham MP (2019): Harnessing reliability for neuroscience research. *Nat Hum Behav* 3:768–771.
- [48] Faul F, Erdfelder E, Buchner A, Lang AG (2009): Statistical power analyses using g\*power 3.1: tests for correlation and regression analyses. *Behav Res Methods* 41:1149–60.
- [49] Cohen J (1969): *Statistical power analysis for the behavioural sciences*. San Diego, CA: Academic Press.
- [50] Sheline YI, Barch DM, Price JL, Rundle MM, Vaishnavi SN, Snyder AZ, *et al.* (2009): The default mode network and self-referential processes in depression. *Proc Natl Acad Sci U S A* 106:1942–7.
- [51] Harris JJ, Reynell C (2017): How do antidepressants influence the bold signal in the developing brain? *Dev Cogn Neurosci* 25:45–57.
- [52] Windischberger C, Lanzenberger R, Holik A, Spindelegger C, Stein P, Moser U, *et al.* (2010): Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. *Neuroimage* 49:1161–70.
- [53] Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, *et al.* (2003): The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). *JAMA* 289:3095–105.
- [54] Viguera AC, Baldessarini RJ, Friedberg J (1998): Discontinuing antidepressant treatment in major depression. *Harv Rev Psychiatry* 5:293–306.
- [55] Kaymaz N, van Os J, Loonen AJM, Nolen WA (2008): Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. *J Clin Psychiatry* 69:1423–36.
- [56] Lythe KE, Moll J, Gethin JA, Workman CI, Green S, Lambon Ralph MA, *et al.* (2015): Self-blame-selective hyperconnectivity between anterior temporal and subgenual cortices and prediction of recurrent depressive episodes. *JAMA Psychiatry* 72:1119–26.
- [57] Teasdale JD, Dent J (1987): Cognitive vulnerability to depression: an investigation of two hypotheses. *Br J Clin Psychol* 26:113–26.
- [58] Lau MA, Segal ZV, Williams JMG (2004): Teasdale's differential activation hypothesis: implications for mechanisms of depressive relapse and suicidal behaviour. *Behav Res Ther* 42:1001–17.
- [59] Segal ZV, Kennedy S, Gemar M, Hood K, Pedersen R, Buis T (2006): Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. *Arch Gen Psychiatry* 63:749–55.
- [60] Ochsner KN, Gross JJ (2005): The cognitive control of emotion. *Trends Cogn Sci* 9:242–9.
- [61] Green S, Lambon Ralph MA, Moll J, Zakrzewski J, Deakin JFW, Grafman J, *et al.* (2013): The neural basis of conceptual-emotional integration and its role in major depressive disorder. *Soc Neurosci* 8:417–33.
- [62] Treynor W, Gonzalez R, Nolen-Hoeksema S (2003): Rumination reconsidered: A psychometric analysis. *Cognitive Therapy and Research* 27:247–259.

- [63] Aldao A, Nolen-Hoeksema S, Schweizer S (2010): Emotion-regulation strategies across psychopathology: A meta-analytic review. *Clin Psychol Rev* 30:217–237.
- [64] Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE (2012): Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. *Neuroimage* 59:2142–54.
- [65] Caballero-Gaudes C, Reynolds RC (2017): Methods for cleaning the bold fmri signal. *Neuroimage* 154:128–149.

## Supplementary Material

### S1 Supplementary Methods

#### S1.1 In- and Exclusion Criteria

Participants fulfilling the following inclusion criteria were eligible for participation in the study:

1. age 18-55 years
2. ability to consent and adhere to the study protocol
3. written informed consent
4. fluent in written and spoken German.

Patients had to additionally fulfil the following criteria:

1. currently under medical care with a psychiatrist or general practitioner for remitted Major Depressive Disorder and willing to remain in care for the duration of the study (approx. 9 months)
2. informed choice to discontinue medication (including willingness to taper the medication over at most 12 weeks) that was independent of study participation
3. clinical remission (Hamilton Depression Score of less than 7) had been achieved under therapy with Antidepressant Medication (ADM) without having undergone manualized psychotherapy; with no other concurrent psychotropic medication and had been maintained for a minimum of 30 days,
4. consent to information exchange between treating physician and study team members regarding inclusion/exclusion criteria and past medical history.

Any of the following exclusion criteria led to exclusion of an participant. This included the following general criteria

1. any disease of type and severity sufficient to influence the planned measurement or to interfere with the parameters of interest (This includes neurological, endocrinological, oncological comorbidities, a history of traumatic or other brain injury, neurosurgery or longer loss of consciousness.)
2. premenstrual syndrome (ICD-10 N94.3).

and MRI-related criteria

1. MRI-incompatible metal parts in the body,
2. inability to sit or lie still for a longer period,
3. possibility of presence of any metal fragments in the body,
4. pregnancy,
5. pacemaker, neurostimulator or any other head or heart implants,
6. claustrophobia and
7. dependence on hearing aid.

For patients the following additional criteria would led to exclusion:

1. current psychotropic medication other than antidepressants,

2. questionable history of major depressive episodes without complicating factors,
3. current acute suicidality,
4. lifetime or current axis II diagnosis of borderline or antisocial personality disorder,
5. lifetime or current psychotic disorder of any kind, bipolar disorder,
6. current posttraumatic stress disorder, obsessive compulsive disorder, or eating disorder
7. current drug use disorder (with the exception of nicotine) or within the past 5 years.

Healthy controls were excluded if there was a lifetime history of Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.)(1) axis I or axis II disorder with the exception of nicotine dependence.

## **S1.2 Questionnaires and Clinical Assessments**

Clinical in- and exclusion criteria were assessed with the Structured Clinical Interview for DSM-IV (SCID) I and II to diagnose axis I disorders (major mental disorders) and axis II disorders (personality disorders), respectively(2). The Structured Interview Guide for Hamilton Depression Rating Scale (SIGH-D)(3) consisting of 17 items was used to assess inclusion and the Inventory of Depressive Symptomatology Clinician Rated (IDS-C)(4) with 30 items to quantify residual depression. Additionally, we applied the German version of the Response Style Questionnaire (RSQ-10D)(5) measuring brooding and reflection as components of rumination with 5 items each.

## **S1.3 Data Analysis**

All analyses, except for the preprocessing of the imaging data, were performed using Matlab version 2016b.

We computed an overall measure of disease severity as the first principal component of number of past depressive episodes, age at illness onset, time in remission, time since depression onset, severity of last episode, time sick in total and time sick in the last five years as variables.

Medication load was based on the dose prior to discontinuation divided by the maximal allowed dose according to the Swiss compendium ([www.compendium.ch](http://www.compendium.ch)) and by the weight of the participant.

Psychotherapy score was coded such that patients with no psychotherapy within the year before the study received a 0, patients reporting to have completed a psychotherapy within one year before the study a 0.5 and patients reporting to be in psychotherapy at the beginning of the study as 1. Significance was computed with a three-way chi-squared test.

## **S1.4 Image Acquisition**

Images were acquired at the two study sites using a Phillips 3T Ingenia in Zurich and a Siemens 3T Trio in Berlin. Participants were instructed to stay awake, keep their eyes open and look at a centrally placed fixation cross.

In Zurich, a 32-channel coil was used to acquire echo-planar images (EPIs; 136 volumes; 40 axial slices; 2.5mm slice thickness; descending sequential acquisition, repetition time: 2560 ms; echo time: 27, field of view: 210 x 210 x 119.5, acquisition matrix: 84 x 82, reconstructed voxel size: 2.19 x 2.19 x 2.50 mm, flip angle: 90°). Additionally, we acquired T1-weighted magnetization-prepared rapid-acquisition gradient-echo (MPRAGE) structural images (301 axial slices; slice thickness: 1; repetition time: 7.9ms; echo time: 3.7ms, field of view: 250 x 250 x 180.6, acquisition matrix: 252 x 251, reconstructed voxel size: 0.98 x 0.98 x 0.60 mm, flip angle: 8°).

In Berlin, a 32-channel coil was used for functional resting-state EPIs (136 volumes; 40 axial slices; 3mm slice thickness including a gap of 0.5mm; descending sequential acquisition, repetition time: 2560 ms; echo time: 27 ms, field of view: 210 x 210 x 120, acquisition matrix: 84 x 84, voxel size: 2.50 x 2.50 x 2.50 mm, flip angle: 90°). T1-weighted MPRAGE structural images (192 axial slices; slice thickness: 1mm; repetition time: 1900 ms; echo time: 2.52 ms, field of view: 256 x 256 x 192, acquisition matrix: 256 x 256, reconstructed voxel size: 0.98 x 0.98 x 0.60mm, flip angle: 9°) were also acquired.

## **S1.5 Preprocessing**

Functional images were realigned, slice-time corrected and smoothed with a 6mm FWHM kernel using adaptive spatial procedure (SUSAN(6)) in FSL (FMRIB Software Library v5.0). The images were then co-registered to the structural image and normalised using Advanced Normalization Tools (ANTs(7)). Finally, an independent component analysis-based artefact removal (ICA-AROMA(8)) was applied to exclude noise components relating e.g. to breathing and heart rate, using a data-driven approach and the data was subjected to a high-pass filter of 0.008Hz. Lastly, BOLD data were normalised to MNI standard space, applying the registration matrices and warp images from the two previous registration steps, and then resampled into 2 mm isotropic voxels. All imaging data were visually inspected to exclude acquisition artefacts or other data corruption.

## **S1.6 Motion correction**

As group differences can be confounded by head motion differences(9), we excluded participants from all analyses if their frame-wise displacement (FD) from one volume to the next exceeded 1mm at any time during the scan. To test for the effects of motion, we performed a median-split based on the mean FD and compared RSFC for all seeds between all participants included at MA1. In case effects were negligible, we used 6 realignment parameters as motion regressors on the first level and no further correction to avoid over-fitting and power reduction. In case non-negligible motion artefacts were observed, we would have additionally added the 6 derivatives of the realignment parameters and censored those scans for which FDs were bigger than 0.5. Censoring scans means to include an additional regressor for each volume at which the movement exceeds a given threshold, here 0.5 FD. This regressors contains zeros at all volumes but the volume that exceeds the threshold. At that volume, the regressor contains a one.

## **S1.7 Study site effects**

To examine systematic differences between the two study sites, we compared the temporal signal-to-noise ratio in the grey matter for all included subjects between sites.

## **S1.8 Sanity checks and exploratory analyses**

To specifically examine effects of time, paired t-test in patients who did not discontinue but were assessed twice (group 12W) were conducted.

To explore whether we missed strong abnormalities that were outside our restricted search volume, i.e. the affective mask, which might be of interest for future studies, we repeated all second level analyses without the affective mask in whole-brain analyses. In addition, we report results without correction for multiple comparison

for number of seeds and uncorrected results at a significance level of 0.001 for all main seed analyses to allow for estimates of potential type II errors.

## S2 Supplementary Results




Figure S1: Site effects: Depicted is the average signal-to-noise ratio (SNR) within the individual grey matter masks over the time of the resting-state period. Dots indicate individual data points, red error bars show standard errors and green error bars show 95% confidence intervals.

### S2.1 Quality checks

To ensure that functional connectivity between our chosen seeds and the anticipated networks based on the literature was evident, we visually inspected the networks connected to the seeds in all participants included for analyses at MA1. Figure S2 depicts these networks for all seeds in the left hemisphere. Network functional connectivity seems as expected.

### S2.2 Effects of time

There were no significant changes in RSFC for any of the seeds in patients who were assessed twice prior to discontinuation.






Figure S2: Functional connectivity networks of all left-sided seeds: sgACC = subgenual anterior cingulate cortex; PCC = posterior cingulate cortex, dlPFC = dorsolateral prefrontal cortex

### **S2.3 Whole-brain exploratory analyses**

Repeating all second level analyses without the affective mask led to the similar significant clusters as reported for the within mask analyses, whereas the p-values naturally differed (parietal cortex:  $p=0.021$ , PCC:  $p=0.004$ ). Of note, no additional effects emerged.

### **S2.4 Uncorrected results**

Table S1 depicts results for all main seeds considered significant at 0.001 without correction. The sparsity of results at this significance level speaks against a high rate of type II error due to correction for multiple comparison, but supports the null hypotheses for many of the examined effects.

Table S1: Significant results at uncorrected level for main seeds

Ssed	Contrast	BA/Region	Peak MNI coordinates			k	p (uncor.)	T-Value	Z	p (FWE-cor., peak)
			x	y	z					
<b>left sgACC</b>	T-test for Pat - HC	Left BA 10	-34	48	14	1	0.001	3.26	3.19	0.821
	T-test for HC - Pat	Left BA 8	-34	22	58	1	0.001	3.30	3.22	0.795
	T-test for No Rel - Rel	Right BA 19	48	-72	26	11	< 0.001	3.60	3.45	0.612
	T-test for No Rel - Rel	Right sensory assoc.	28	-42	64	1	0.001	3.25	3.11	0.942
<b>left PCC</b>	F-test discontinuation	Left BA 7	-38	-48	56	26	< 0.001	4.35	4.19	0.059
	F-test discontinuation	Right amygdala	16	-2	-18	8	< 0.001	3.56	3.47	0.522
	F-test discontinuation	Right amygdala	24	4	-26	2	< 0.001	3.53	3.44	0.556
	F-test discontin. x rel.	Right BA 10	40	58	-8	3	< 0.001	3.78	3.57	0.432

T-tests are independent sample t-tests. F-tests show interactions for the discontinuation effect and the discontinuation x relapse interaction effect. BA = Brodmann area, MNI = Montreal Neurological Institute, sgACC = subgenual anterior cingulate cortex, HC = healthy controls, Pat. = patients, No Rel = no relapse, Rel = relapse, PCC = posterior cingulate cortex

## References

- [1] American Psychiatric Association (2000): *Diagnostic and Statistical Manual of Mental Disorders 4th ed., text rev.* Washington, DC: Author.
- [2] Wittchen HU, Fydrich T (1997): *Strukturiertes klinisches Interview für DSM-IV. Manual zum SKID-I und SKID-II.* Göttingen, DE: Hogrefe.
- [3] Williams JB (1988): A structured interview guide for the hamilton depression rating scale. *Arch Gen Psychiatry* 45:742–7.
- [4] Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996): The inventory of depressive symptomatology (IDS): psychometric properties. *Psychol Med* 26:477–86.
- [5] Huffziger S, Kühner C (2012): Die Ruminationsfacetten Brooding und Reflection: Eine psychometrische Evaluation der deutschsprachigen Version RSQ-10D. *Z Klin Psychol und Psychother* 41:38–46.
- [6] Smith SM, Brady JM (1997): SUSAN - A new approach to low level image processing. *Int J Comput Vis* 23:45–78. ISSN 0920-5691.
- [7] Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC (2011): A reproducible evaluation of ants similarity metric performance in brain image registration. *Neuroimage* 54:2033–44.
- [8] Pruim RHR, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF (2015): ICA-AROMA: A robust ICA-based strategy for removing motion artifacts from fMRI data. *Neuroimage* 112:267–277.
- [9] Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE (2012): Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. *Neuroimage* 59:2142–54.